Published on August 20, 2014

Serious doubts on policy implementation is expected to rise as the domestic pharmaceutical industry is getting affected through pricing and regulatory issues and a short-term solution will definitely be brought through price controls to an affordability of certain medicines, however they might sustain in long run, according to the industry experts. Moreover on 10th July 2014 the National Pharmaceutical Pricing Authority (NPPA) with no warning to the pharma manufacturer had randomly preset the prices for all cardiovascular and anti-diabetic drugs, exterior the scope of the Drug Price Control Order (DPCO) 2013.

According to the industry experts, for investors the out-dated healthcare system and creaking of India is noted as the main concerns, however the landscape is still eye-catching, moreover rising wealth in the midst of growing middle class, technologically advanced workforce and increased health awareness are noted as the influential apparatus for expansion. Furthermore as per the researched report, by the year 2020 sales of pharmaceutical are predicted to rise by 15% to USD 56 billion from a current level of USD 21 billion.

As per the researched report, currently in the world India is noted as the most competitive pharmaceutical market in the midst of several alternatives and a wealthy generics industry for each drug that is available at different price points, moreover through an unexpected move of the regulators and arbitrary the long-term health and structure of this sector is being intimidate.

According to the sources, for pharmaceuticals, evaluating applications seeking intellectual property rights (IPR) the government will not replace present structure of guidelines however will revise the guidelines and along with proceedings between the generic drug producers and innovator companies, this is likely to follow an growing number of drug patent filings.